Trending...
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
WESTON, Fla., May 28, 2024 ~ Cantex Pharmaceuticals, Inc. has recently announced that their drug, azeliragon, will be featured in four abstracts at the 2024 ASCO Annual Meeting in Chicago. The company, which focuses on developing transformative therapies for cancer and other life-threatening medical conditions, is excited to showcase the progress of their clinical investigations at leading cancer centers.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
- King Dumpsters Canton Launches Affordable, Reliable Dumpster Rental Services in Canton, Ohio
- Matthew Cossolotto's The Joy of Public Speaking – Helping Readers Move from Stage Fright to Stage Delight – Wins 2024 Maincrest Media Book Award
- Lady Bird Laser Spa: Empowering Beauty with Advanced Skin Treatments and Exceptional Service
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- The Champagne Connection Podcast Episode Spotlights the Transformative Journey of NASA Scientist
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Century Fasteners Corp. Mourns the Loss of Colleague and Friend, Mark James
- COLORICH PACKAGING Will Participate in the COSME Week 2025 TOKYO and Cosmoprof Worldwide Bologna 2025 Exhibition
- Red Alert: Transform U Media Network Exposes the Shocking Truth About Red Dye No. 3
- IntellaTriage Launches New Patient Engagement Service
- Momentum Stock Trading: AI-Driven by Tickeron
- Various Measures Introduced to and Approved by the Chicago City Council
- IntellaTriage Launches New Patient Engagement Service
- Naperville Police Accepting Applications for Spring 2025 Citizen Police Academy
- Cascadia Global Security Launches Cascadia Off-Duty
- Anti-Racism Song from Neal Fox Drops in Time for Martin Luther King Day
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- Ajust Design Establishes Chicago Headquarters to Meet Growing Demand for Strategic Design Solutions in Private Capital Markets
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- City Of Chicago Responds To S&P Credit Rating Adjustment
- Orcas Island Property Owner Returns Two Prime Waterfront Properties to the Market
- Muench Workshops Welcomes New Partners Luke Dray and Sara Linssen, Announces Retirement of Andy Williams